⚠ For informational purposes only — not a substitute for professional medical advice. Emergencies: 911 or Poison Control 1-800-222-1222.
Drug Identification System
Home Blog Compare Interactions Search
ADHD Medication Guide · 12 Medications Compared

ADHD Medications —
Stimulants vs Non-Stimulants

ADHD medications work by targeting the dopamine and norepinephrine systems in the brain's prefrontal cortex — the region responsible for executive function, working memory, and impulse control. The two main treatment approaches are stimulants (which work on the first day they are taken) and non-stimulants (which build effect over weeks). This guide covers 12 medications in clinical depth, including the critical pharmacological difference between amphetamines and methylphenidates.

How ADHD medications work: In ADHD, the prefrontal cortex is relatively under-stimulated due to dysregulation in dopamine and norepinephrine signaling. Stimulant medications increase the availability of both neurotransmitters in the synapse — strengthening the "signal" in circuits that govern attention, behavioral inhibition, and working memory. Non-stimulants target norepinephrine specifically (atomoxetine, viloxazine) or act on alpha-2A adrenergic receptors to directly modulate prefrontal neuron firing (guanfacine, clonidine). The resulting improvement in prefrontal function allows for better top-down control of attention and impulse.

12 Medications Covered 8 Stimulants · 4 Non-Stimulants Amphetamines · Methylphenidates Non-Stimulants Available Rx Only
Key pharmacological distinction

Amphetamines vs Methylphenidates

These are both stimulant classes, and both increase dopamine and norepinephrine — but by fundamentally different mechanisms. This distinction has real clinical implications for how each feels, how long it lasts, and which patients respond better to which class.

Amphetamines

Dopamine & NE Releasers

  • Enter the presynaptic neuron and cause active release of dopamine and norepinephrine from storage vesicles
  • Also reverse the reuptake transporter (DAT/NET), pumping neurotransmitters out into the synapse
  • Effect is more robust and more pronounced than reuptake inhibition alone
  • Includes: Adderall (mixed salts), Vyvanse (lisdexamfetamine), Dexedrine (dextroamphetamine)
  • Generally produce larger effect sizes on ADHD symptoms per mg equivalent
  • More pronounced appetite suppression than methylphenidates at comparable doses
Methylphenidates

Dopamine & NE Reuptake Inhibitors

  • Block the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing reuptake
  • Neurotransmitters that were already released remain in the synapse longer — but no extra release is triggered
  • Mechanism is more similar to cocaine than amphetamines (also a DAT blocker), though pharmacokinetics are far slower
  • Includes: Ritalin (IR), Concerta (ER), Focalin (dexmethylphenidate), Daytrana (patch)
  • Some patients who don't respond to one class respond well to the other
  • Generally shorter duration than amphetamine-class equivalents
Side-by-side comparison

All ADHD Medications at a Glance

Scroll horizontally on small screens. Duration estimates are typical ranges — individual metabolism varies. Color-coded by drug class: purple = amphetamine, blue = methylphenidate, amber = non-stimulant.

Drug (Brand) Class Schedule Duration Mechanism Notable Features
Mixed Amphetamine Salts IR Adderall Amphetamine Stimulant IR Schedule II 4–6 hrs DA/NE releaser Most widely prescribed stimulant. 75% d-amp, 25% l-amp. Multiple twice-daily dosing often needed. Generic widely available.
Mixed Amphetamine Salts XR Adderall XR Amphetamine Stimulant ER Schedule II 8–10 hrs DA/NE releaser 50% IR beads / 50% delayed-release beads. Once-daily morning dosing. Capsule can be opened and sprinkled on food.
Lisdexamfetamine Vyvanse Amphetamine Stimulant ER · Prodrug Schedule II 10–14 hrs Prodrug → DA/NE releaser Requires RBC enzymatic conversion to active d-amphetamine. Smoother onset/offset. Lower abuse potential. Also FDA-approved for binge eating disorder. Most expensive; no generic.
Dextroamphetamine Dexedrine · Zenzedi Amphetamine Stimulant IR/ER Schedule II 4–6 hrs (IR), 6–8 hrs (ER) DA/NE releaser Pure d-amphetamine — the more pharmacologically active isomer. Slightly more potent per mg than mixed salts. Dexedrine Spansules are the ER form.
Methylphenidate IR Ritalin · Methylin Methylphenidate Stimulant IR Schedule II 3–5 hrs DA/NE reuptake inhibitor First-line option; most studied stimulant class in children. Short duration often requires 2–3x daily dosing. Generic broadly available.
Methylphenidate ER Concerta Methylphenidate Stimulant ER Schedule II 8–12 hrs DA/NE reuptake inhibitor OROS technology: 22% immediate-release coating + 78% osmotically-released ER core. Most-studied long-acting methylphenidate. Tablet must be swallowed whole.
Dexmethylphenidate Focalin · Focalin XR Methylphenidate Stimulant IR/ER Schedule II 4–5 hrs (IR), 8–10 hrs (XR) DA/NE reuptake inhibitor d-isomer of methylphenidate only (racemic mix contains l-threo which is inactive). Theoretically effective at roughly half the milligram amount of racemic MPH.
Methylphenidate Patch Daytrana Methylphenidate Stimulant · Transdermal Schedule II ~12 hrs (worn 9 hrs) DA/NE reuptake inhibitor Applied to hip; worn 9 hours. Effect persists ~3 hours after removal. Useful for children who cannot swallow pills. Skin reactions common with prolonged use at same site.
Atomoxetine Strattera Non-Stimulant NE Reuptake Inhibitor Not Controlled Full effect at 4–6 weeks Selective NE reuptake inhibitor First non-stimulant FDA-approved for ADHD. No abuse potential. Good for comorbid anxiety. FDA black box warning for suicidality in children/adolescents.
Guanfacine ER Intuniv · Tenex (IR) Non-Stimulant Alpha-2A Agonist Not Controlled Full effect at 2–4 weeks Alpha-2A adrenergic agonist Also approved for hypertension. Helpful for emotional dysregulation, aggression, hyperactivity, tics. Frequently added to stimulants for adjunct coverage. Less sedating than clonidine.
Clonidine ER Kapvay · Catapres (IR) Non-Stimulant Alpha-2 Agonist Not Controlled Full effect at 2–4 weeks Alpha-2 adrenergic agonist Broader alpha-2 activity than guanfacine; more sedating. Kapvay is ER for ADHD; Catapres IR for hypertension. Also used for tics + ADHD. Useful for stimulant-related insomnia when given at bedtime.
Viloxazine ER Qelbree Non-Stimulant NE Reuptake Inhibitor Not Controlled Full effect at 4–6 weeks Selective NE reuptake inhibitor Newest non-stimulant; FDA-approved 2021. Significant CYP1A2 inhibitor — may raise levels of caffeine, theophylline, and some antipsychotics. Not controlled. Approved for children 6+ and adults.

All ADHD medications require a prescription. Duration estimates are population averages; individual pharmacokinetics vary meaningfully. This table does not constitute dosing guidance.

Individual drug profiles · Amphetamines

Amphetamine-Class Medications

The purple accent bar identifies amphetamine-class agents. All are Schedule II controlled substances. As a class, amphetamines produce larger dopamine and norepinephrine increases than methylphenidates at equipotent doses.

Mixed Amphetamine Salts IR Adderall
Class Amphetamine
ADHD Schedule II 4–6 hr Duration Generic Available

Adderall IR is the most widely prescribed stimulant for ADHD in the United States. Its active ingredients are a mixture of four amphetamine salts — 75% dextroamphetamine (d-amphetamine) and 25% levoamphetamine (l-amphetamine) — spanning both enantiomers of amphetamine. The d-isomer has greater CNS potency and a more pronounced effect on dopamine; the l-isomer contributes more to norepinephrine and peripheral (cardiovascular) effects.

The mechanism is active release: amphetamines enter the presynaptic terminal through the dopamine transporter (DAT), displace dopamine from storage vesicles, and trigger the transporter to run in reverse — flooding the synapse with dopamine and norepinephrine. This is fundamentally different from, and more powerful than, simple reuptake inhibition.

The short 4–6 hour duration means most patients require dosing two or three times daily for consistent coverage. Available in 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg, and 30mg tablets. Widely available as generic at substantially lower cost than brand-name extended-release formulations.

Clinical note: Some patients intentionally prefer IR formulations for their ability to time coverage precisely — taking a dose only when task demands require it, and allowing the afternoon window to be stimulant-free. Others find the on/off cycle disruptive.

Mixed Amphetamine Salts XR Adderall XR
Class Amphetamine
ADHD Schedule II 8–10 hr Duration Once Daily

Adderall XR contains the same mixed amphetamine salts as the IR formulation, but delivered via a dual-bead extended-release system. Each capsule contains two types of beads in equal proportion: 50% are immediate-release beads that dissolve promptly after swallowing, and 50% are delayed-release beads coated to dissolve approximately 4 hours later — essentially producing two sequential IR doses from one capsule.

The result is a longer effective window of approximately 8–10 hours, allowing once-daily morning dosing for most patients. This eliminates the need for a midday dose at school or work — a practical advantage that can meaningfully affect adherence and reduce stigma around midday dosing for children. The capsule can be opened and the beads sprinkled on applesauce for patients who cannot swallow capsules, but the beads should not be chewed.

Available in 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules. Generic Adderall XR is available and has improved access substantially since the brand-name patent expired. Periodic national shortages of both brand and generic amphetamine products have been a recurring issue since 2022.

Lisdexamfetamine Vyvanse
Class Amphetamine · Prodrug
ADHD Binge Eating Disorder Schedule II 10–14 hr Duration

Vyvanse represents a genuinely different pharmacological approach to amphetamine delivery. Lisdexamfetamine is a prodrug — the amphetamine molecule is covalently bonded to the amino acid lysine, rendering it pharmacologically inert until it reaches the bloodstream. Red blood cell enzymes then cleave the lysine, releasing d-amphetamine at a rate governed by the enzymatic conversion process rather than the immediate dissolution of the drug.

This prodrug mechanism has several practical consequences. First, it produces a smoother, more gradual onset and offset compared to conventional amphetamine formulations — many patients describe the effect as less "peaky." Second, the 10–14 hour duration is longer than any other single oral amphetamine formulation. Third — and most clinically significant for the Schedule II classification — crushing or snorting Vyvanse does not meaningfully increase its rate of absorption or produce a faster "rush," because the conversion still requires red blood cell enzymatic activity regardless of the route of administration. This makes it inherently less susceptible to the abuse patterns common with other stimulants.

Vyvanse is the only ADHD stimulant with an additional FDA-approved indication: moderate-to-severe binge eating disorder in adults. It remains brand-only (a generic became available in 2023 after patent expiration). Available in 20mg, 30mg, 40mg, 50mg, 60mg, and 70mg capsules and chewable tablets.

Cost context: Vyvanse has historically been the most expensive brand-name stimulant. Generic lisdexamfetamine significantly reduces cost, though availability can vary by pharmacy.

Dextroamphetamine Dexedrine · Zenzedi
Class Amphetamine
ADHD Schedule II 4–6 hr (IR), 6–8 hr (ER)

Dextroamphetamine is pure d-amphetamine — the dextrorotatory isomer — without the levoamphetamine component found in mixed amphetamine salts. The d-isomer has significantly greater CNS activity and contributes most of the therapeutic effect of mixed salts; the l-isomer contributes more to peripheral (cardiovascular and sympathomimetic) activity. On a per-milligram basis, pure dextroamphetamine is somewhat more potent than mixed amphetamine salts for ADHD symptom control.

Dexedrine Spansules are the extended-release capsule form, delivering effect over 6–8 hours. Zenzedi is an immediate-release tablet formulation available in a range of lower strengths that allows more precise titration — particularly useful for patients who respond to low amounts or who need careful dose adjustments. Available in 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, and 30mg tablets (Zenzedi) and 5mg, 10mg, and 15mg Spansule capsules.

Dextroamphetamine is sometimes preferred for patients who experience prominent peripheral side effects (racing heart, blood pressure elevation) on mixed amphetamine salts, since removing the l-amphetamine may reduce cardiovascular effects while preserving CNS efficacy.

Individual drug profiles · Methylphenidates

Methylphenidate-Class Medications

The blue accent bar identifies methylphenidate-class agents. All are Schedule II controlled substances. Methylphenidates are reuptake inhibitors — they do not cause active release of dopamine. Some patients respond preferentially to this class over amphetamines, and vice versa.

Methylphenidate IR Ritalin · Methylin
Class Methylphenidate
ADHD Schedule II 3–5 hr Duration Generic Available

Methylphenidate IR is one of the most studied medications in pediatric pharmacology, with clinical trial data spanning more than 60 years. It works by blocking the dopamine transporter (DAT) and norepinephrine transporter (NET), preventing the reuptake of dopamine and norepinephrine that have already been released naturally into the synapse. Unlike amphetamines, it does not trigger active release from storage vesicles.

The short 3–5 hour duration is the defining practical limitation of IR methylphenidate. Most patients require 2–3 daily doses to maintain coverage across the school or work day, and the school-nurse dispensing of midday doses has long been a logistical and privacy challenge for children. Despite this, IR formulations remain valuable for their flexibility — a late-day dose can be skipped if evening stimulant effects would disrupt sleep.

Methylphenidate is a racemic mixture of d- and l-threo-methylphenidate; the d-isomer is the pharmacologically active component. Available in 5mg, 10mg, and 20mg tablets (Ritalin); Methylin is available in additional forms including chewable tablets and an oral solution — useful for younger children or those with swallowing difficulties.

Methylphenidate ER Concerta
Class Methylphenidate
ADHD Schedule II 8–12 hr Duration Once Daily OROS Technology

Concerta uses OROS — Osmotic Release Oral System — a proprietary delivery technology that produces a distinctive release pattern. The tablet has an immediate-release coating containing 22% of the total dose, providing a prompt therapeutic effect upon swallowing. The remaining 78% is contained in a compartment inside the tablet. As water from the gastrointestinal tract enters through a semipermeable membrane, it pushes the medication out through a laser-drilled hole at a controlled rate over 8–12 hours.

The OROS system is designed to produce a gradually ascending blood level throughout the day — intended to counteract the tolerance that can develop when drug levels remain flat for hours. The tablet must be swallowed whole; crushing or chewing would destroy the delivery mechanism and release the full dose at once. The empty tablet shell (the OROS osmotic pump mechanism) is inert and passes through the GI tract intact — patients occasionally notice this in the stool, which is normal and not a sign that the drug wasn't absorbed.

Concerta is the most extensively studied long-acting methylphenidate formulation. Available in 18mg, 27mg, 36mg, and 54mg tablets. Some generic versions of Concerta have faced scrutiny over bioequivalence and release profile fidelity — the FDA has maintained Concerta's rated generics require specific OROS technology to carry a "B" rating.

Dexmethylphenidate Focalin · Focalin XR
Class Methylphenidate
ADHD Schedule II 4–5 hr (IR), 8–10 hr (XR)

Dexmethylphenidate is the d-threo enantiomer of methylphenidate isolated alone — the pharmacologically active half of the racemic mixture. Standard methylphenidate contains both d-threo (active) and l-threo (largely inactive) isomers; Focalin removes the inactive l-threo component, leaving only the active d-isomer. This means dexmethylphenidate is approximately twice as potent per milligram as racemic methylphenidate on a theoretical basis.

In practice, the dose-equivalence relationship with racemic methylphenidate is not perfectly 2:1 — individual responses vary — but the d-isomer formulation allows for lower absolute milligram doses, which some patients and prescribers prefer. The pharmacokinetic profile is otherwise similar to the racemic parent compound.

Focalin XR uses a bead technology similar to Adderall XR: a 50/50 split of immediate-release and delayed-release beads producing extended coverage over 8–10 hours from a single morning dose. Available in 2.5mg, 5mg, and 10mg tablets (IR) and 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules (XR). Generic dexmethylphenidate is available.

Methylphenidate Patch Daytrana
Class Methylphenidate · Transdermal
ADHD Schedule II ~12 hr Effect (9 hr Wear) Skin Reactions

Daytrana is the only transdermal methylphenidate formulation available. The patch is applied to the hip each morning and worn for 9 hours; because methylphenidate continues to be absorbed through the skin for approximately 3 hours after removal, the effective duration of action extends to roughly 12 hours. Removing the patch early is one method to intentionally shorten the duration of effect — for example, when evening stimulant effects need to be minimized for sleep.

The primary advantage is the route of administration: it completely eliminates the need to swallow a pill. This makes it particularly useful for children who have significant difficulty swallowing tablets or capsules, or for patients who reliably forget or refuse oral medication. Absorption is relatively consistent once steady-state skin saturation is reached.

The main drawback is skin reactions. Local erythema and irritation at the application site are common; contact sensitization (an immune reaction to the adhesive or drug) can develop with prolonged use, and in some cases may cause chemical leukoderma — permanent lightening of the skin at the application site. The patch should be rotated to a different spot on the opposite hip each day. Available in 10mg, 15mg, 20mg, and 30mg (per 9 hr) strengths.

Skin Sensitization

If significant irritation, rash, or blistering develops at the application site, contact the prescriber before continuing use. In rare cases, permanent skin color changes can occur with prolonged use at the same site. Rotate application sites daily.

Non-stimulant medications

Non-Stimulants: When and Why

Non-stimulants are not the first choice for most patients with ADHD — stimulants are more effective on average. But non-stimulants fill important clinical roles where stimulants are contraindicated, poorly tolerated, or where additional benefits are needed.

When non-stimulants are preferred

Clinical Situations Favoring Non-Stimulants

Non-stimulants offer meaningful advantages for specific patient populations and clinical scenarios. Unlike stimulants, which require a Schedule II prescription with monthly prescriber visits and no refills, non-stimulants are not controlled substances — meaning prescriptions can be called in, refilled, and managed with greater administrative flexibility.

Key Indications for Non-Stimulant Treatment
  • Comorbid anxiety disorder — stimulants can worsen anxiety; atomoxetine and viloxazine have neutral to beneficial anxiety profiles
  • Active substance use disorder or significant abuse history — no controlled substance prescribing concerns
  • Significant cardiovascular contraindications to stimulants (uncontrolled hypertension, arrhythmias)
  • Tics or Tourette syndrome — guanfacine and clonidine specifically reduce tic frequency
  • Stimulant-related insomnia — guanfacine or clonidine added to stimulant at bedtime helps sleep onset
  • Emotional dysregulation and aggression — alpha-2 agonists are specifically helpful here
  • Need for 24-hour coverage without stimulant rebound
  • Patient or family preference to avoid controlled substances

Atomoxetine

Strattera · Generic Available

The first non-stimulant specifically FDA-approved for ADHD (2002). Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) — it blocks NET but has negligible affinity for DAT, unlike stimulants. Effect builds over 4–6 weeks of consistent dosing. Carries a black box warning for suicidality in children and adolescents, similar to antidepressants — patients should be monitored for mood changes early in treatment. No abuse potential; not a controlled substance. Particularly useful when comorbid anxiety is present, as the mechanism is compatible with anxiolytic benefit. Poor metabolizers of CYP2D6 (about 7% of Caucasians) may have higher drug levels and stronger effects.

Guanfacine ER

Intuniv · Guanfacine IR → Tenex

Guanfacine is an alpha-2A adrenergic receptor agonist — it mimics norepinephrine at these receptors, which are densely expressed on prefrontal pyramidal neurons. Stimulating alpha-2A receptors strengthens the "network connectivity" of prefrontal circuits underlying working memory and impulse control. Intuniv (ER formulation) is FDA-approved for ADHD; Tenex (IR) is approved for hypertension and used off-label for ADHD. Guanfacine ER is often added to a stimulant to extend coverage into evenings, smooth out rebound, and help with emotional dysregulation. Less sedating than clonidine due to its specificity for the 2A subtype. Takes 2–4 weeks for full effect. Do not stop abruptly — rebound hypertension can occur.

Clonidine ER

Kapvay · Clonidine IR → Catapres

Clonidine is an alpha-2 agonist with broader receptor activity than guanfacine — it binds alpha-2A, 2B, and 2C subtypes, as well as imidazoline receptors. This broader binding makes it more sedating than guanfacine, which some patients find problematic during the day and others find useful at bedtime. Kapvay (ER) is FDA-approved for ADHD; Catapres (IR) is approved for hypertension. Frequently used for ADHD + tics (Tourette syndrome). The evening/bedtime use of low-dose clonidine to help with stimulant-related sleep onset difficulties is a common and well-supported clinical strategy. Like guanfacine, should not be stopped abruptly due to rebound hypertension risk.

Viloxazine ER

Qelbree · FDA-Approved 2021

Viloxazine is the newest FDA-approved ADHD medication (2021 for children 6–17; 2023 expanded to adults). Like atomoxetine, it is a selective norepinephrine reuptake inhibitor. A key clinical consideration is its significant inhibition of CYP1A2 — the enzyme that metabolizes caffeine, theophylline, some antipsychotics (olanzapine, clozapine), and other drugs. Co-administration with CYP1A2 substrates can raise those drugs' levels substantially. Unlike atomoxetine, viloxazine does not carry a black box warning for suicidality, though monitoring for mood changes is still appropriate. Not a controlled substance; available in 100mg, 150mg, and 200mg extended-release capsules that can be opened and sprinkled on food.

Side effect profiles

Side Effects by Category

Stimulant side effects are largely class-wide — they occur with both amphetamines and methylphenidates, though often to differing degrees. Non-stimulants have distinct side effect profiles. None of what follows constitutes a complete list; discuss your specific situation with a prescriber.

🍽️

Appetite Suppression

The most common stimulant side effect. Both amphetamines and methylphenidates reduce appetite, with amphetamines typically producing stronger effects. Most prominent at peak drug levels — patients often have little interest in lunch but regain appetite in the evening ("stimulant rebound hunger"). In children, this raises concerns about adequate nutrition and growth. Strategies include eating breakfast before the medication takes effect, offering calorie-dense foods in the evening, and monitoring height/weight trajectories in growing children.

😴

Insomnia

Difficulty falling asleep is common, particularly with late-day doses or longer-acting formulations taken too late in the morning. The stimulant effect on norepinephrine promotes wakefulness, which can persist into the evening. Management includes optimizing the timing of the last dose, switching to shorter-acting formulations for the afternoon dose, or adding guanfacine or low-dose clonidine at bedtime. Some patients paradoxically report improved sleep quality on stimulants if their ADHD-related hyperarousal was previously disrupting sleep.

❤️

Cardiovascular Effects

Stimulants reliably increase heart rate (typically 3–10 bpm) and blood pressure (typically 2–4 mmHg) on average. For most healthy patients, these changes are clinically insignificant. They become relevant in patients with pre-existing hypertension, arrhythmias, structural heart disease, or family history of sudden cardiac death. Baseline cardiovascular assessment is recommended before starting stimulants, and monitoring is ongoing. Sudden death has been reported in patients with serious structural cardiac abnormalities — prescribers should screen for these before prescribing.

🔄

Rebound / Comedown

As stimulant levels drop in the late afternoon or evening, some patients experience a transient worsening of ADHD symptoms beyond their pre-medication baseline — irritability, emotional lability, fatigue, increased hyperactivity. This "rebound" effect is more common with shorter-acting formulations and with higher doses. Strategies include a small afternoon booster dose of an IR stimulant, switching to a longer-acting formulation, or adding a non-stimulant for evening coverage. The rebound is not universal — many patients simply return to their unmedicated baseline.

📏

Growth in Children

Long-term stimulant use in children is associated with modest reductions in expected height velocity — estimated at roughly 1–2 cm over years of treatment. This effect appears related to appetite suppression reducing caloric intake, and possibly direct effects on growth hormone. Pediatric patients on long-term stimulants should have height and weight monitored at regular intervals. The long-term clinical significance of this growth effect remains debated; most studies find no significant difference in final adult height between treated and untreated individuals with ADHD.

⚠️

Abuse Potential

All stimulant ADHD medications are Schedule II precisely because of their abuse potential — they can produce euphoria at high doses or when taken by non-prescribed individuals, and physical dependence can develop. Among formulations, immediate-release products have higher abuse potential than extended-release ones due to faster onset; Vyvanse (lisdexamfetamine) has the lowest abuse potential among amphetamines due to its prodrug design. Non-stimulants have no recognized abuse potential and are not scheduled. Appropriate use as prescribed for ADHD at therapeutic doses does not appear to increase the lifetime risk of substance use disorder.

Non-stimulant side effects differ significantly: atomoxetine and viloxazine commonly cause nausea, decreased appetite, and fatigue early in treatment. Guanfacine and clonidine can cause sedation, hypotension, bradycardia, and dizziness — particularly when first starting or increasing the dose. Alpha-2 agonists should not be stopped abruptly due to rebound blood pressure elevation.
Controlled substance considerations

DEA Schedule II: Practical Implications

All stimulant ADHD medications are classified as Schedule II controlled substances by the DEA — the most restrictive schedule for substances with accepted medical use. This classification has concrete administrative implications for patients and prescribers.

DEA Schedule II Requirements

What Schedule II Means in Practice

Schedule II classification reflects that these drugs have a high potential for abuse that may lead to severe psychological or physical dependence. For ADHD patients, this translates to a set of requirements that differ significantly from non-controlled prescriptions.

Administrative Requirements
  • No refills: Schedule II prescriptions cannot be refilled — a new prescription must be written for every supply. This typically means a monthly prescriber appointment or at minimum a monthly contact for a new written prescription.
  • No phone-in or fax prescriptions (generally): Schedule II prescriptions must be written on a tamper-resistant prescription form, or transmitted electronically via certified e-prescribing for controlled substances (EPCS) where state law permits.
  • Prescription Drug Monitoring Program (PDMP): Pharmacists and prescribers are required to check the PDMP before dispensing or prescribing. The PDMP logs every controlled substance prescription filled, preventing patients from obtaining prescriptions from multiple providers simultaneously.
  • Quantity limits: Most states limit Schedule II prescriptions to a 30-day supply. Some states allow up to 90 days for maintenance therapy in specific circumstances.
  • DEA registration required: Only prescribers with a current DEA license may prescribe Schedule II medications. Prescribers' DEA numbers are tied to specific locations.
  • Telemedicine restrictions: Prescribing stimulants via telemedicine without a prior in-person evaluation was subject to pandemic-era relaxations that have been extended; the regulatory landscape continues to evolve — check with your prescriber or pharmacy for current rules.

Non-stimulant ADHD medications (atomoxetine, guanfacine, clonidine, viloxazine) are not scheduled controlled substances. They can be prescribed with refills, called in by phone, and managed with standard prescription workflows — a meaningful advantage for some patients and in some clinical settings.

Adult ADHD considerations

Adults with ADHD

The same medications are used in adults as in children, but several clinical considerations shift. ADHD in adults was underrecognized for decades; many adults receive their first diagnosis in their 30s, 40s, or later.

Cardiovascular Screening

More Weight in Adults

The modest blood pressure and heart rate increases from stimulants are more clinically significant in adults, who are more likely to have pre-existing hypertension, atherosclerosis, or cardiac disease. Cardiovascular evaluation before starting stimulants is standard practice. Patients with uncontrolled hypertension, recent myocardial infarction, or significant arrhythmias may be directed toward non-stimulant options. Regular blood pressure monitoring during treatment is appropriate.

Substance Use Comorbidity

Complex Risk-Benefit

ADHD substantially increases the lifetime risk of substance use disorders. Adults presenting for ADHD evaluation with active substance use or a significant history require thoughtful prescribing. Non-stimulants (atomoxetine, viloxazine, guanfacine) are often preferred in this setting because they carry no abuse potential. If stimulants are appropriate, longer-acting formulations with lower abuse potential (Vyvanse, Concerta) may be preferred over short-acting IR agents. Treating ADHD effectively may itself reduce substance use by addressing the impulsivity and dysregulation that drive it.

Occupational Impact

Functional Coverage Timing

Adults often need different coverage timing than children. A professional who works 9–7 may need extended coverage that a school schedule does not require. Some adults need evening coverage for homework help with their own children, managing finances, or maintaining relationships — not just work productivity. The optimal formulation, timing, and any afternoon booster dose should be worked out around the patient's actual daily schedule rather than a default protocol.

Late Diagnosis Considerations

Different Starting Point

Adults newly diagnosed with ADHD often arrive with decades of developed coping strategies — some adaptive, some maladaptive. They may have built careers, relationships, and routines around their unmedicated ADHD brain. Medication may reveal new challenges (the stimulant effect can feel unfamiliar or anxiety-provoking initially) and create new opportunities. Adults also metabolize medications differently than children and may respond to different strength ranges. The pharmacological treatment is often most effective when combined with ADHD coaching or cognitive-behavioral strategies.

Frequently asked questions

Common Questions About ADHD Medications

What's the difference between Adderall and Vyvanse?
Both Adderall and Vyvanse are amphetamine-based stimulants, but they differ in how they deliver amphetamine to the body. Adderall contains mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) that are immediately active upon absorption. Vyvanse (lisdexamfetamine) is a prodrug — it is pharmacologically inactive until red blood cell enzymes cleave the lysine molecule attached to the d-amphetamine. This conversion process produces a smoother, more gradual onset and a longer, more consistent duration (10–14 hours vs 4–6 hours for Adderall IR, 8–10 hours for Adderall XR). The prodrug design also means Vyvanse cannot be effectively abused by crushing or snorting, since the conversion requires enzymatic activity in the bloodstream. Vyvanse also has an additional FDA approval for moderate-to-severe binge eating disorder. Adderall is available as a generic and is less expensive; Vyvanse became available as generic in 2023 but may still carry a higher cost depending on insurance and pharmacy.
Are non-stimulants as effective as stimulants for ADHD?
For most patients, stimulants are more effective than non-stimulants for ADHD. Meta-analyses consistently show that stimulants (amphetamines and methylphenidates) produce larger effect sizes on ADHD symptom reduction than non-stimulants. However, "less effective on average" does not mean "ineffective" — non-stimulants work well for many patients and offer advantages in specific situations. Non-stimulants are often preferred when a patient has comorbid anxiety (stimulants can worsen anxiety), there is a history of substance use disorder (non-stimulants have no abuse potential), a patient cannot tolerate stimulant side effects, tics are present (guanfacine and clonidine are specifically helpful here), or the patient needs 24-hour coverage without a stimulant on/off pattern. Non-stimulants also take longer to show full effect — atomoxetine and viloxazine require 4–6 weeks of consistent dosing, unlike stimulants which work on the first day.
Can ADHD medications cause addiction?
The stimulant ADHD medications are Schedule II controlled substances with recognized potential for misuse and dependence when taken in ways other than prescribed — at much higher doses, by non-prescribed individuals, or by routes other than oral. However, research on patients who take them as prescribed for ADHD paints a different picture: studies have consistently found that appropriate treatment of ADHD with stimulants does not increase the lifetime risk of substance use disorders, and some research suggests it may reduce that risk by addressing the underlying impulsivity and dysfunction that predispose some individuals to substance use. Physical dependence (tolerance and withdrawal symptoms on abrupt discontinuation) can develop with long-term use. Non-stimulants — atomoxetine, guanfacine, clonidine, and viloxazine — are not controlled substances and have no recognized abuse potential. The distinction between physical dependence and addiction (compulsive use despite consequences) is important: dependence on a medically supervised regimen is a different clinical situation than addiction.
What happens if a person without ADHD takes an ADHD stimulant?
In individuals without ADHD, stimulant medications produce a more pronounced euphoria and increase in energy than in those with the condition — partly because the dysregulated dopamine system in ADHD responds differently than a neurotypical one. This is one reason stimulants have high misuse potential when used without a prescription. The subjective experience for a non-ADHD person is more likely to include a recognizable "high," increased heart rate and blood pressure, reduced appetite, and disrupted sleep. Cognitive "enhancement" in neurotypical individuals is often overstated — studies of stimulant use in healthy volunteers show modest or inconsistent improvements on complex cognitive tasks, and some research shows impaired performance when taken at higher doses. Taking stimulants without a prescription is illegal (Schedule II), and the risks — cardiovascular strain, psychiatric side effects, potential for dependence — apply regardless of ADHD diagnosis.
Why does my ADHD medication wear off in the afternoon?
The late-day wearing off of ADHD medication — sometimes called the "rebound" effect — happens because stimulant blood levels drop as the medication is metabolized. For extended-release formulations, the transition from therapeutic levels to sub-therapeutic levels as the drug clears can paradoxically produce a brief worsening of symptoms or irritability beyond baseline before the brain re-equilibrates. Several strategies are used clinically: adding a small afternoon booster dose of an IR stimulant, switching to a longer-acting formulation, trying a different medication class, or adding a non-stimulant (particularly guanfacine or clonidine, which are often added to stimulants specifically to smooth out coverage and manage evening rebound). The optimal approach depends on the individual's schedule, sleep, and side effect profile, and should be worked out with the prescriber.
Further reading
Blog · ADHD

ADHD Medications Guide: Stimulants vs Non-Stimulants

 Blog · DEA Schedules

DEA Drug Schedules Explained

 Blog · Drug Testing

How Long Does Adderall Stay in Your System?
Medical Disclaimer

This page is for general informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. No content on this page constitutes a recommendation to use, avoid, or change any medication. ADHD medications are prescription-only drugs that require evaluation and monitoring by a qualified healthcare provider. Stimulant medications are DEA Schedule II controlled substances — their use, possession, and distribution without a valid prescription is illegal. Always consult a licensed prescriber before making any decisions about ADHD treatment. In a medical emergency, call 911. For poison control, call 1-800-222-1222.

© PillID · Privacy · Terms · Sitemap

Information on this site is for educational use only. Always consult a qualified healthcare provider before making medical decisions.